Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

Roteli-Martins, Cecília Maria; Naud, Paulo; Borba, Paola Colares de; Teixeira, Júlio César; Carvalho, Newton Sérgio de; Zahaf, Toufik; Sánchez, Nervo; Geeraerts, Brecht; Descamps, Dominique

doi:10.4161/hv.18865

Cited by 179 publications

(136 citation statements)

References 23 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…15 Here, a similar trend was predicted for the HPV-16/18 vaccine by the modified power-law model; a plateau in antibody responses at approximately 18 months after initial vaccination and a long-term immune response with antibody titers predicted to be sustained above those associated with natural infection.…”

mentioning

confidence: 50%

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Einstein

Takács

Chatterjee

et al. 2014

Human Vaccines & Immunotherapeutics

106

View full text Add to dashboard Cite

mentioning

confidence: 50%

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Einstein

Takács

Chatterjee

et al. 2014

Human Vaccines & Immunotherapeutics

106

View full text Add to dashboard Cite

“…Fortunately, among vaccinated individuals, the rates of reported adverse events have been comparable to rates among placebo recipients and within expected background rates in the general population 56 . In addition, the latest trial results indicate that protection has endured unabated for nearly a decade (for licensed hpv vaccines) and longer (approximately 13 years for the prototype hpv 16 vaccine) without any indication of waning antibodies [57][58][59] . Finally, epidemiology studies investigating the potential for hpv type replacement (that is, the scenario in which other hpv types take over the niches vacated by the eradication of vaccine target types) have so far provided no strong evidence of natural type competition, which is considered a requirement for type replacement to occur in vaccinated populations 60 .…”

Section: Hpv Vaccination: a New Paradigm In Cervical Cancer Preventionmentioning

confidence: 99%

The Road Ahead for Cervical Cancer Prevention and Control

et al. 2014

View full text Add to dashboard Cite

Since the early 1950s, Papanicolaou (“Pap”) cytology screening has dramatically reduced cervical cancer mortality in most high-income settings. Currently, human papillomavirus (hpv) vaccination has the greatest potential to reduce the global burden of cervical cancer and precancerous lesions. However, as the prevalence of precancerous lesions declines, maintaining cytology as the primary screening test in settings with established programs might become less efficient. A reduction in test performance (sensitivity, specificity, and positive predictive value) would lead to an increase in unnecessary colposcopy referrals. Fortunately, hpv dna testing has emerged as a suitable candidate to replace cytology. Compared with the Pap test, hpv testing is less specific but much more sensitive in detecting high-grade precancerous lesions, less prone to human error, and more reproducible across settings. Linkage of hpv vaccination and screening registries could serve the added role of monitoring vaccine efficacy. As a triage test, cytology is expected to perform with sufficient accuracy because most hpv-positive smears would contain relevant abnormalities. This approach and others—for example, hpv testing followed by genotyping—are being evaluated in large population studies and have already been recommended in some settings. Other specific biomarkers that might perform well for screening and triage include hpv E6/ E7 messenger rna testing, methylation of host or viral genes, and p16INK4a staining. Considering the rapid pace of major discoveries and the anticipated arrival of a nonavalent hpv vaccine (currently in phase iii trials), the evidence base in this field has become an elusive target and will continue to be an obstacle for policymakers.

show abstract

“…A large number of clinical trials have proven that these vaccines are safe, well tolerated, highly immunogenic, and effective in preventing persistent infections by HPV vaccine types as well as cervical intraepithelial lesions associated with them (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia

Cómbita

Gheit

González

et al. 2016

Cancer Prevention Research

View full text Add to dashboard Cite

Urine sampling for HPV DNA detection has been proposed as an effective method for monitoring the impact of HPV vaccination programs; however, conflicting results have been reported. The goal of this study was to evaluate the performance of optimized urine HPV DNA testing in women aged 19 to 25 years. Optimization process included the use of first void urine, immediate mixing of urine with DNA preservative, and the concentration of all HPV DNA, including cell-free DNA fragments. Urine and cervical samples were collected from 535 young women attending cervical screening at health centers from two Colombian cities. HPV DNA detection and genotyping was performed using an HPV type-specific multiplex genotyping assay, which combines multiplex polymerase chain reaction with bead-based Luminex technology. Concordance between HPV DNA detection in urine and cervical samples was determined using kappa statistics and McNemar tests. The accuracy of HPV DNA testing in urine samples was evaluated measuring sensitivity and specificity using as reference the results obtained from cervical samples. Statistical analysis was performed using STATA11.2 software. The findings revealed an overall HPV prevalence of 60.00% in cervical samples and 64.72% in urine samples, HPV-16 being the most frequent HPV type detected in both specimens. Moreover, our results indicate that detection of HPV DNA in first void urine provides similar results to those obtained with cervical samples and can be used to monitor HPV vaccination trials and programs as evidenced by the substantial concordance found for the detection of the four vaccine types.Cancer Prev Res; 9(9); 766-71. Ó2016 AACR.

show abstract

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

Cited by 179 publications

References 23 publications

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

The Road Ahead for Cervical Cancer Prevention and Control

Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia

Contact Info

Product

Resources

About